Neuropathic pain arises due to damaged or diseased nervous system and results in sensations such as burning, stabbing or shooting pain, numbness and tingling. Neurostimulation therapies including transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation and deep brain stimulation are being used to modulate pain signals and manage neuropathic pain symptoms. Neuropathic pain disorders are becoming more prevalent attributed to rising incidence of diabetes, cancer, HIV/AIDS and spinal cord injuries.
The Global Neuropathic Pain Market is estimated to be valued at US$ 7.56 Billion in 2023 and is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030).
Key Takeaways
Key players operating in the neuropathic pain market are Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc. Key players are focusing on developing novel drug delivery systems and minimally invasive neurostimulation therapies to expand their product portfolios.
Growing prevalence of diabetic neuropathy and cancer-related pain presents lucrative Neuropathic Pain Market opportunities for gene therapies and devices combining neuromodulation with drug delivery hold promising prospects. Several clinical trials are underway for cannabinoid-based and gene therapies expected to bring efficacious options.
Technological advancements including implants integrated with microelectronics and closed-loop feedback systems are enabling customized, responsive neurostimulation therapies with reduced side effects. Wearable devices and smartphone-controlled stimulators also provide greater convenience and discretion for patients.
Market Drivers
Rising geriatric population susceptible to neuropathic disorders like diabetes and arthritis is a key factor driving market growth. According to WHO, by 2050 over 2 billion people will be aged 60 years and above. Increasing incidence of diabetes due to obesity and sedentary lifestyles also contributes to market expansion. Other macroeconomic factors promoting the market include growth in healthcare expenditure per capita worldwide and availability of innovative product offerings.
Current challenges in the Neuropathic Pain Market:
The development of effective treatment options for neuropathic pain has been challenging due to its complex nature. Neuropathic pain arises due to damage or disease affecting the nervous system. It is often chronic and unpredictable in nature. Identifying the exact cause or mechanisms involved is difficult. Developing therapies targeting specific biological pathways is complicated by the multiple factors that can trigger or maintain neuropathic pain. Drug resistance is another issue, with many patients not achieving adequate pain relief or experiencing side effects of current therapies. High placebo response rates in clinical trials also make it challenging to demonstrate the efficacy of new treatment approaches.
SWOT Analysis
Strength: Availability of multiple drug classes targeting neuropathic pain including antidepressants, anticonvulsants and opioid analgesics provides treatment options. Growing understanding of the biological basis of neuropathic pain is aiding drug development.
Weakness: Current therapies only provide moderate pain relief for many patients. Safety issues are posed by long-term use of medications. High development costs and regulatory hurdles hamper introduction of new drugs.
Opportunity: Unmet needs indicate scope for more effective and safer medications. Research into novel targets and delivery approaches can help address unresolved issues. Growing geriatric population prone to neuropathic conditions increases the market potential.
Threats: Intense competition between pharmaceutical companies limits scope for high prices and profits. Generic competition erodes sales of off-patent drugs. Social factors like opioid abuse crisis impact usage of certain classes of analgesics.
Geographical regions where market in terms of value is concentrated:
North America currently accounts for the largest share of the global neuropathic pain market, due to growing prevalence of neuropathic disorders, strong reimbursement structure, and high adoption of advanced pain therapies in the region.
Fastest growing region:
Asia Pacific region is expected to grow at the fastest rate during the forecast period. Factors such as rising healthcare expenditure, growing awareness about chronic pain conditions, increasing disposable incomes, and expansion of healthcare facilities in developing countries are driving the market in this region.
Get More Insights On Neuropathic Pain Market
Get this Report in Japanese Language
Get this Reports in Korean Language
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor’s degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya’s meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)